science2 publishers
Stanford's all-agent biotech put one AI agent on each of 37,075 clinical trials
James Zou's agent company read the results of tens of thousands of finished trials and found that drugs aimed at switch-like, cell-type-specific targets reached market about 48% more often. No experiment has tested that yet.
Reality
- Evidence58
- Adoption22
- Hype gap+32
- Incentives60
- Confidence62